

## Press Release

### **Astellas Confirms Final Federal Circuit Decision in LEXISCAN<sup>®</sup> 0.4 mg/mL U.S. Patent Appeal**

**TOKYO, May 11, 2023** – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today confirmed that the Court of Appeals for the Federal Circuit (CAFC) issued a Mandate that officially ends the CAFC appeal on patent infringement of LEXISCAN<sup>®</sup> (regadenoson injection) 0.4 mg/mL.

On May 3, 2023, the CAFC denied our petitions for rehearing and rehearing en banc of the CAFC’s December 30, 2022 Opinion that affirmed the U.S. District Court for the District of Delaware’s earlier decision that all asserted claims of the patents for LEXISCAN<sup>®</sup> are not infringed by Hospira, Inc.

Astellas has already reflected the impact from this decision in its financial forecast of the current fiscal year ending March 31, 2024.

For more information, please see [the press release issued on May 20, 2022](#), [the press release issued on September 26, 2022](#) and [the press release issued on January 21, 2023](#).

#### **About Astellas**

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach which is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+<sup>®</sup> healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands at the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at <https://www.astellas.com/en>.

#### **Cautionary Notes**

In this press release, statements made concerning current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs considering the information currently available to it and involve known and unknown risks and uncertainties. Several factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products

accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) included in this press release is not intended to constitute an advertisement or medical advice.

###

---

**Contacts for inquiries or additional information:**

Astellas Pharma Inc.  
Corporate Advocacy & Relations  
+81-3-3244-3201